Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Public ClinicalTrials.gov record NCT00908349. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Study identification
- NCT ID
- NCT00908349
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Interventions
- Oxcarbazepine XR Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 66 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Oct 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- May 30, 2017
2009 – 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Northport | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | West Los Angeles | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Missoula | Montana | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Baytown | Texas | — | — |
| Not listed | Temple | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00908349, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00908349 live on ClinicalTrials.gov.